First successful clinical trial of VU319 brings Alzheimer's treatment one step closer
December 19, 2024
December 19, 2024
NASHVILLE, Tennessee, Dec. 19 -- Vanderbilt University issued the following news:
Researchers at the Warren Center for Neuroscience Drug Discovery, a clinical stage biotech within the Vanderbilt University School of Medicine Basic Sciences, have detailed the successful drug discovery of a Phase I Single Ascending Dose clinical trial of VU319, a drug for memory loss in people with Alzheimer's disease and schizophrenia.
"This milestone highlights Vanderbilt's ability . . .
Researchers at the Warren Center for Neuroscience Drug Discovery, a clinical stage biotech within the Vanderbilt University School of Medicine Basic Sciences, have detailed the successful drug discovery of a Phase I Single Ascending Dose clinical trial of VU319, a drug for memory loss in people with Alzheimer's disease and schizophrenia.
"This milestone highlights Vanderbilt's ability . . .